source
- Nouscom secures $135 million Series D to advance lead cancer vaccine into Phase 2Clinical-stage biotech Nouscom announced it has closed a $135 million Series D financing round that was oversubscribed. The capital will be used to move its lead cancer vaccine candidate into a Pha…
- ESMO 2026 preview spotlights upcoming abstracts from Zai Lab, GSK and MerckThe European Society for Medical Oncology (ESMO) meeting returns to Madrid in 2026, featuring a slate of abstracts expected from several major biotech and pharmaceutical companies. Among the antic…